Sage Journals: Discover world-class research

Abstract

Polymeric conjugates of 5-fluorouracil (5-FU) were synthesized by covalent attachment of tetrapeptide chains with 2-(5-fluorouracil-1-yl)glycine ethyl ester [Gly(FU)OEt] as the C-terminus, to poly(ethylene glycol) (PEG) and dextran (Dex). Cytotoxicity of these conjugates was compared with free 5-FU against the murine colorectal carcinoma cell line C26. All the conjugates displayed lower cytotoxicity than 5-FU. The chemical structure and the configuration of the tetrapeptide chains influenced the activity of the conjugates. Materials containing the tetrapeptide Gly-Phe-Gly-Gly(FU)OEt (l,d), with Dex-based conjugates were more cytotoxic than the analogue PEG-based conjugate. PEG-Gly-Phe-Gly-Gly(FU)OEt (l,d) administered to mice at doses of 150 and 250 mg 5-FU equivalent/kg, following by inoculation of C26 tumor cells, mediated much less toxicity than equivalent doses of free 5-FU. The anticancer activity achieved using free and polymer-bound drugs were comparable, although decreased toxicity of the conjugate should facilitate administration of increased doses with improved efficacy.

Get full access to this article

View all access options for this article.

References

1. Bundgaard H. , "The double prodrug concept and its applications." Adv. Drug. Deliv. Rev. 3:39-65, 1989.

2. Ringsdorf H. , "Structure and properties of pharmacologically active polymers." J. Polymer Sci. Symposia 51:135-, 1975.

3. Sesaki H. , Takakura Y. and Hashida M. , "Soluble macromolecular carriers for the delivery of antitumor drugs." Adv. Drug Deliv. Rev. 3:247-, 1989.

4. Calabresi P. and Parks Jr. R.E. , "Antimetabolites." In: Pharmacological Basis of Therapeutics (Eds., Goodman L.S. , Sarkar F.H. , Crissman J.D. and Fridman R. ) pp. 1268-1276, McMillan New York, 1985.

5. Akashi M. and Takemoto K. , "New aspects of polymer drugs." Adv. Polymer Sci. 97:108-146, 1990.

6. Ouchi T. , Fujino A. , Tanaka K. and Banba Y. , "Synthesis and antitumor activity of conjugates of poly(a-malic acid) and 5-fluorouracil bound via ester, amide or carbamoyl bonds." J. Controlled Release 12:143-153, 1990.

7. Ouchi T. , Hagihara Y , Takashi K. , Takano Y and Igarashi I. , "Synthesis and antitumor activity of poly(ethylene glycol)s linked to 5-fluorouracil via urethane or urea bonds," Drug Design Discovery 9:93-105, 1992.

8. Ouchi T. , Banba T. , Matsumoto T. , Suzuki S. and Suzuki M. , "Synthesis and antitumor activity of conjugates of 5-fluorouracil and chito-oligosaccharides involving a hexamethylene spacer group and carbamoyl bonds." Drug Design Delivery 6:281-287, 1990.

9. Nichifor M. , Coessens V. and Schacht E. H. , "Macromolecular prodrugs of 5-fluorouracil. 1. Synthesis and hydrolytic stability." J. Bioact. Comp. Polymers 10:199-222, 1995.

10.

10. Nichifor M. , Seymour L. W. and Schacht E. H. , "Macromolecular prodrugs of 5-fluorouracil. 2. Enzymatic degradation." J. Controlled Release 39:79-92, 1996.

11.

11. Choksakulnimitr S. , Masuda S. , Tokuda H. , Takakura Y and Hashida M. , "In vitro cytotoxicity of macromolecules in different cell culture systems." J. Controlled Release 34:233-241, 1995.

12.

12. Katre N. V. , "The conjugation of proteins with polyethylene glycol and other polymers." Adv. Drug Deliv. Rev. 10:91-114, 1993.

13.

13. Nakajima N. and Ikada Y. , "Effects of concentration, molecular weight, and exposure time of polyethylene glycol) on cell fusion." Polymer J. 27:211-219, 1995.

14.

14. Milburn Jessup J. , "Cathepsin B and other proteases in human colorectal carcinoma." Am. J. Patol 145:253-262, 1994.

15.

15. Campo E. , Munoz J. , Miquel R. , Palacin A. , Cardesa A. , Sloane B.Y. and Emmert-Buck M.R. , "Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival." Am. J. Patol 145:301-309, 1994.

16.

16. Caliceti P , Monfardini C. , Sartore L. , Schiavon O. , Baccichetti F , Carlassare F and Veronese F.M. , "Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer." Il Farmaco 48:919-932, 1993.

17.

17. Chu B.C.F. and Whiteley J.M. , "High molecular weight derivatives of methotrexate as chemotherapeutic agents. " Mol. Pharmacol 13:80-88,1977.

18.

18. Dang W , Colvin O.M. , Brem H. and Saltzman W.M. , "Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix." Cancer Res. 54:1729-1735, 1994.

19.

19. Seynour L.W. , Duncan R. , Strohalm J. and Kopecek J. , "Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats." J. Biomed Mater. Res. 21:1341-1358, 1987.

20.

20. Seymour L.W. , "Passive tumor targeting of soluble macromolecules and drug conjugates." Crit. Rev. Therapeut. Drug Carrier Syst. 9:135-187, 1992.

21.

21. Matsumura Y and Maeda H . "A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS." Cancer Res. 46:6387-6393, 1986.

Cytotoxicity and Anticancer Activity of Macromolecular Prodrugs of 5-Fluorouracil

Abstract

Get full access to this article

References